Monitor for continuity in financial strategy and investor communications. The reiteration of guidance suggests stability, but the combination of a CFO change and recent proxy fight warrants scrutiny of upcoming financial reports for any deviations from stated projections.
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 14 $29.29entry
- T+1 · 7mo ago −0.24%α −1.01% · $29.22
- T+5 · 7mo ago +9.73%α +8.34% · $32.14
- T+20 · 6mo ago +3.04%α −3.26% · $30.18
- T+60 · 4mo ago +30.45%α +21.93% · $38.21
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Harmony Biosciences announced the departure of CFO Sandip Kapadia and the immediate appointment of Glenn Reicin as his replacement. The company reiterated its 2026 net revenue guidance of $1.0–1.04 billion. This leadership transition follows a recent proxy fight, suggesting ongoing board-level tensions.
Key Facts
- CFO Sandip Kapadia stepped down effective April 14, 2026, after serving since 2021
- Glenn Reicin appointed as new CFO effective immediately, with a $500,000 base salary and $3 million option grant
- Kapadia's separation agreement includes $539,000 severance and accelerated vesting of October 2023 equity awards
- Company reaffirmed 2026 net revenue guidance of $1.0–1.04 billion
- This change follows a contested 2026 proxy election, indicating potential governance tensions
Financial Impact
Approximately $3.5 million in total separation and onboarding costs (severance, equity acceleration, and new hire grant)
Risk Factors
- Potential disruption during CFO transition
- Ongoing governance tensions following contested proxy vote
- Execution risk if new CFO alters capital allocation strategy
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-042886 |
| Document: hrmy-20260414xex10d2.htm | 0001104659-26-042886 |
| Document: hrmy-20260414x8k.htm | 0001104659-26-042886 |
| Document: hrmy-20260414xex99d1.htm | 0001104659-26-042886 |
| Document: 0001104659-26-042886-index-headers.html | 0001104659-26-042886 |
| Document: 0001104659-26-042886-index.html | 0001104659-26-042886 |
| Document: 0001104659-26-042886.txt | 0001104659-26-042886 |
Track record
20 reports on HRMY
2 of 3 bullish or bearish reports moved the stock their way by T+20. Best: +14.82% at T+20 after the Jul 16, 2026 report. 4 of 5 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 3/10 Entry $33.21 Now $32.96 −0.75% settles Dec 15
- Nov 4, 202612d ago 8-K Bearish 5/10 No price data
- Nov 4, 202612d ago Press Release Bearish 5/10 Entry $34.42 Now $32.96 +4.23% settles Dec 3
- Nov 2, 202614d ago Institutional Cluster Neutral 3/10 Entry $37.02 Now $32.96 −10.97% settles Dec 2
- Oct 30, 202617d ago 8-K/A Neutral 3/10 Entry $37.91 Now $32.96 −13.06% settles Dec 1
- Oct 27, 202620d ago SC 13G/A Neutral 2/10 Entry $38.50 Now $32.96 −14.39% settles Nov 25
- Oct 13, 20264w ago 8-K Neutral 3/10 Entry $37.03 to $33.55 Now $32.96 −10.99% ▼ −9.40% −5.79% vs SPY
- Oct 1, 20266w ago Press Release Neutral 3/10 Entry $39.57 to $38.59 Now $32.96 −16.70% ▼ −2.48% −3.18% vs SPY
- Aug 4, 202614w ago 8-K Bullish 7/10 No price data
- Aug 4, 202614w ago Press Release Bullish 6/10 Entry $38.78 Now $32.96 −15.01% No price data
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers